Download Files:
Pamufetinib
SKU
HY-12423-Get quote
Category Reference compound
Tags c-Met/HGFR;VEGFR, Cancer, Protein Tyrosine Kinase/RTK
Products Details
Product Description
– Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
Web ID
– HY-12423
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C27H23FN4O4S
References
– [1]Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96.|[2]Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9(6):775-83.
CAS Number
– 1190836-34-0
Molecular Weight
– 518.56
SMILES
– O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC(CC4=CC=CC=C4)=O)=S)C=C3F)C2=C1)NC
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– c-Met/HGFR;VEGFR
Isoform
– VEGFR2/KDR/Flk-1
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.